Abstract:Francisella tularensis , the bacterium that causes tularemia, has been a persistent and widespread pathogen in various regions of the world for centuries. Francisella tularensis can affect humans and various domestic and wild animals. The current study aimed to determine the epidemiological status of tularemia in countries of the WHO Eastern Mediterranean Region (EMRO) through a systematic review and meta-analysis. All included studies were identified through a systematic search of online databases, including Scopus, PubMed, Web of Science, and EMBASE, through July 26, 2022, using keywords and suitable combinations. We focused on cross-sectional studies investigating the prevalence of F . tularensis . The weighted pooled prevalence was calculated using a random-effects model. A total of 206 studies were identified, of which 20 were finally included in the analysis. The human seroprevalence of tularemia in WHO-EMRO countries was 6.2% (95% CI, 4.2 9.2). In the subgroup analysis, anti- F . tularensis antibodies were found in 6.92% and 5.5% of the high-risk individuals and Iran, respectively. The pooled prevalence of F . tularensis in environmental samples (water and soil) from the WHO-EMRO countries was 5.8% (9.4% by PCR and 0.5% by culture). In addition, 2.5% (95% CI, 0.2 0.22.7) of ticks in WHO-EMRO countries were positive for F . tularensis . The pooled prevalence of F . tularensis in rodents is 2.0% (1.1% by PCR and 3.7% by serology). In addition, 0.6% of domestic ruminants (0.4% by PCR and 2.4% by serology) were positive for F . tularensis in WHO-EMRO countries. According to the results of the present study, tularemia is an endemic but neglected disease in the WHO-EMRO region. However, most studies on tularemia are limited to a few countries in this region. Studies on tularemia in human populations, reservoirs, and vectors have been conducted in all countries in the WHO-EMRO region to obtain more detailed information about the epidemiology of tularemia in these regions. Tularemia is a bacterial zoonotic disease caused by Francisella tularensis . This bacterium can infect animals (domestic and wild vertebrates), invertebrates, and humans. Francisella tularensis is transferred to humans through contact with infected wild animals (, inhalation of infected aerosols, arthropod bites, consumption of contaminated water or contaminated food, and swimming and contact in polluted hydro-telluric environments. The mortality rate associated with this disease ranges from 2 to 60% in the absence of proper antibiotic treatment. The prevalence of F . tularensis varies significantly between countries, as these pathogens can infect a wide range of hosts and have multiple vectors. However, there needs to be complete data on the geographical distribution of different species of F . tularensis , as well as the status of reservoirs, vectors, and human cases in most parts of the world. Therefore, this study aimed to determine F . tularensis prevalence in the countries of the WHO Eastern Mediterranean Region (WHO-EMRO). Based on our study, the human seroprevalence of tularemia in WHO-EMRO countries was 6.2%. The pooled prevalence of F . tularensis in environmental samples (water and soil), ticks, rodents, and domestic ruminants were 5.8%, 2.5%, 2.0%, and 0.6% in the WHO-EMRO countries, respectively.

Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009–2018

Surveillance of antibiotic resistance in clinical isolates from First Affiliated Hospital of Zhejiang University Medical College in 2009

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023

Tularemia Clinical Manifestations, Antimicrobial Treatment, and Outcomes: An Analysis of US Surveillance Data, 2006–2021

Evolution of Antibiotic Resistance in Surrogates of Francisella tularensis (LVS and Francisella novicida): Effects on Biofilm Formation and Fitness

Analysis of Antimicrobial Resistance of 266 Escherichia Coli

Francisella tularensis Bone and Joint Infections: United States, 2004–2023

Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients.

Tularemia treatment: experimental and clinical data

Tolfenpyrad Derivatives Exhibit Potent Francisella-Specific Antibacterial Activity without Toxicity to Mammalian Cells In Vitro

Functional characterization of Francisella tularensis subspecies holarctica genotypes during tick cell and macrophage infections using a proteogenomic approach

Tularemia: A Storied History, An Ongoing Threat

Epidemiology of tularemia in the countries of the WHO Eastern Mediterranean Region (EMRO): A systematic review and meta-analysis

Non-vaccinal prophylaxis of tularemia

Current vaccine strategies and novel approaches to combatting Francisella infection

Tularemia - a re-emerging disease with growing concern

Antimicrobial susceptibility patterns of community-acquired uropathogenic Escherichia coli, Dublin 2010–2022

1367. Resistance to Ceftriaxone and Ciprofloxacin in Nontyphoidal Salmonella from Humans and Relatedness to Isolates from Animal Sources

Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes from an 11-year Retrospective Observational Cohort in Northern Sweden

In Vitro Susceptibility of Escherichia Coli Strains Isolated from Urine Samples Obtained in Mainland China to Fosfomycin Trometamol and Other Antibiotics: a 9-Year Surveillance Study (2004–2012)